Pemetrexed + cisplatin (malignant pleural mesothelioma, 1L)

Name: Pemetrexed + cisplatin (malignant pleural mesothelioma, 1L) - OpenOnco
License: https://creativecommons.org/licenses/by/4.0/

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PEMETREXED` `DRUG-CISPLATIN`

ID	`REG-PEMETREXED-CISPLATIN-MPM`
Type	Regimen
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	None declared
Sources	None declared

Used By

Indication

IND-MESOTHELIOMA-1L-PEMETREXED-PLATINUM - IND-MESOTHELIOMA-1L-PEMETREXED-PLATINUM

Regimen

REG-NIVO-IPI-MESOTHELIOMA - Nivolumab + ipilimumab (mesothelioma, 1L)

Sources

SRC-EMPHACIS-VOGELZANG-2003 - Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in pat...